Karol Kajo, Karla Scheerová
Testing of HER2 in all invasive carcinomas of the breast is conditio sine qua non for the following therapeutic management. In the praxis, there are two methods of testing of HER2, firstly an immunohistochemical detection of protein expression on the cytoplasmatic membrane is realized in all cases, followed by fluorescent in situ hybridization for assessment of amplification of HER2 gene in selected cases with equivocal immunohistochemical expression of HER2 protein. Review of contemporary possibilities, criteria and requests on HER2 detection, as well as identification and solving of possible problems which are known to be associated with analysis of HER2 status are discussed in the _article. Also questions about the goals of the National programme of HER2 status detection in the Slovak Republic are involved into the discussion.